Recommended

Lilly demonstrates alopecia areata promise in major study
Novartis bets $12bn on potential first-in-class RNA therapeutics
Process analytical tool could aid real-time monitoring in vaccine manufacturing
CPHI Pharma Awards 2025 winners announced
Drug delivery study offers potential “paradigm shift” in restenosis
Lilly AI supercomputer set to advance pharma manufacturing
FDA draft guidance to streamline biosimilar development
Novo Nordisk bids $6.5 billion for Metsera
news

Novo Nordisk makes $1 billion acquisition agreement

7
SHARES

Under a $1 billion acquisition agreement, Novo Nordisk A/S will investigate a potential first-in-class small molecule CB1 receptor blocker as a treatment for obesity.

Novo Nordisk makes $1 billion acquisition agreement

Novo Nordisk A/S has agreed to acquire Inversago Pharma for up to $1.075 billion.

 

Reserve your FREE place

 


Address the time-to-result challenge posed by short shelf-life radiopharmaceuticals.

20 November 2025 | 3:00 PM GMT | FREE Virtual Panel Discussion

This webinar showcases the Growth Direct System; an RMM (Rapid Microbial Method) that improves on traditional membrane filtration, delivering increased accuracy, a faster time to result, enhanced data integrity compliance, and more control over the manufacturing process.

Key learning points:

  • Understand the benefits of full workflow microbiology quality control testing automation in radiopharmaceutical production
  • Learn about ITM’s implementation journey and considerations when evaluating the technology
  • Find out how the advanced optics and microcolony detection capabilities of Growth Direct® technology impact time to result (TTR).

Don’t miss your chance to learn from experts in the industry – Register for FREE

 

Inversago Pharma is developing CB1 receptor-based therapies for the potential treatment of obesity, diabetes and complications associated with metabolic disorders.

What Novo Nordisk will gain from the acquisition

Through the acquisition agreement, the pharma company Novo Nordisk intends to investigate Inversago Pharma’s lead development asset, a potential first-in-class small molecule CB1 receptor (CB1r) blocker CB1 inverse agonist as a treatment for obesity and obesity-related complications.

Potential of INV-202

INV-202 is an oral CB1 inverse agonist. The receptor protein has an important role in metabolism and appetite regulation in peripheral tissues such as adipose tissues, kidneys, the gastro-intestinal tract, liver, pancreas, muscles and lungs.

According to Inversago Pharma, INV-202 demonstrated weight loss potential in its Phase Ib study.

In the company’s first-in-human trial for the treatment, data showed “the safety and tolerability, oral absorption, and pharmacokinetics of INV-202… supported rapid progression into a Phase II study.” A Phase II trial of INV-202 for diabetic kidney disease (DKD) is currently ongoing. Data has also shown the small molecule CB1r blocker illustrated capability for decreased appetite.

CB1 receptor-based therapies are a “promising class of medicine” according to Martin Holst Lange, Executive Vice President for Development at Novo Nordisk, who added that if future development is successful, it “could lead to life-changing new treatment options for those living with a serious chronic disease and, in particular, may offer alternative or complementary solutions for people living with obesity”.

François Ravenelle, Chief Executive Officer of Inversago Pharma commented on the acquisition agreement: “We are delighted to join forces with a global leader in the obesity and metabolic disorder space”.

Closing of the acquisition is subject to receipt of applicable regulatory approvals and other customary conditions and whether certain development and commercial milestones are achieved. The transaction between Novo Nordisk and Inversago is expected to occur before the close of 2023.

Semaglutide demonstrates cardiovascular benefit

Share via
Share via